FDA approves Bayer AG’s Kovaltry for hemophilia A
Kovaltry is designed to reduce bleeding in patients with hemophilia A when infused prophylactically two or three times per week, and was approved by the European Commission on Feb. 22.
Kovaltry is designed to reduce bleeding in patients with hemophilia A when infused prophylactically two or three times per week, and was approved by the European Commission on Feb. 22.
Patients can go up to two weeks between infusions.
George McCoy, a longtime patient at the ºÚÁÏÍø Hemophilia & Thrombosis Center and the first man in the world to receive recombinant clotting factor, was the subject of a news story on WTVD on February 16.
ºÚÁÏÍø's 340B pharmacy's accreditation by URAC became effective February 1, 2016. URAC's mission is to promote continuous improvement in the quality and efficiency of health care management through processes of accreditation, education, and measurement.
In a press release dated January 19, 2016, the International Society on Thrombosis and Haemostasis (ISTH) announced its new international clinical Core Curriculum on thrombosis and hemostasis, the first framework of its kind to define the minimum standards for a medical doctor to attain a level of proficiency to enable them to practice independently as specialists in the field.
Nigel Key, M.D., Director of the ºÚÁÏÍø Hemophilia and Thrombosis Center, is extensively quoted in the January 12, 2016 WebMD article "Hemophilia: New Treatments for an Old Disease," by Sonya Collins.
Brenda Nielsen, RN, nurse in the ºÚÁÏÍø Comprehensive Hemophilia Diagnostic and Treatment Center, will serve a three-year term on this council beginning December 1, 2015 through November 30, 2018.
On October 17, The ºÚÁÏÍø TarHealers walk team raised $5,160 for the Raleigh Hemophilia Walk, which benefits Hemophilia of North Carolina and the National Hemophilia Foundation.
Dr. Key's lecture, which was delivered on Monday, October 19, 2015, was entitled "Thrombosis in Hemolytic Anemias: What are the Common Themes?"
It is with regret that the ºÚÁÏÍø Hemophilia & Thrombosis Center announces the departure of Paul E. Monahan, M.D. after a 25-year association with ºÚÁÏÍø-Chapel Hill. Dr. Monahan received his M.D. in 1990 from the University of Virginia School of Medicine in Charlottesville, VA and completed his Internship/Residency at ºÚÁÏÍø Chapel Hill. Dr. Monahan …